公开(公告)号：WO1996041184A1

公开(公告)日：1996-12-19

申请号：PCT/US1996007617

申请日：1996-05-24

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GRENIER, Frank ,  HOLZMAN, Thomas, F. ,  SMITH, Allan, H. ,  TSURUTANI, Alan, C.

IPC: G01N33/566

CPC classification number: G01N33/96 ,  G01N33/9493 ,  G01N2333/9121 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/102499 ,  Y10T436/106664 ,  Y10T436/107497 ,  Y10T436/108331

Abstract: The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably FKBP, to stabilize the drug in an aqueous matrix.

Abstract translation: 本发明涉及包含具有增强的稳定性的药物，优选他克莫司或雷帕霉素的体外含水组合物。 本发明利用结合蛋白，优选FKBP，将药物稳定在含水基质中。

公开(公告)号：EP0832433A1

公开(公告)日：1998-04-01

申请号：EP96916602.0

申请日：1996-05-24

Applicant: Abbott Laboratories

Inventor： GRENIER, Frank ,  HOLZMAN, Thomas, F. ,  SMITH, Allan, H. ,  TSURUTANI, Alan, C.

IPC: G01N33

CPC classification number: G01N33/96 ,  G01N33/9493 ,  G01N2333/9121 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/102499 ,  Y10T436/106664 ,  Y10T436/107497 ,  Y10T436/108331

Abstract: The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably FKBP, to stabilize the drug in an aqueous matrix.

公开(公告)号：EP0832433B1

公开(公告)日：2002-03-20

申请号：EP96916602.4

申请日：1996-05-24

Applicant: Abbott Laboratories

Inventor： GRENIER, Frank ,  HOLZMAN, Thomas, F. ,  SMITH, Allan, H. ,  TSURUTANI, Alan, C.

IPC: G01N33/566 ,  G01N33/536 ,  G01N33/96

CPC classification number: G01N33/96 ,  G01N33/9493 ,  G01N2333/9121 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/102499 ,  Y10T436/106664 ,  Y10T436/107497 ,  Y10T436/108331

Abstract: The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably FKBP, to stabilize the drug in an aqueous matrix.